According to the Pharmaceutical Benefits Assessment Committee (PBAC) agenda for March 2024, published on 5 January 2024, the meeting will be jammed with biopharma applications for reimbursement. The applications for PBS listing additions or amendments that the PBAC will consider at its March 2024 meeting include the following:
| New Listings | Amendment Applications |
| Janssen-Cilag’s Stelara® (ustekinumab) | Sanofi-Aventis’s Dupixent® (dupilumab) |
| Amgen’s Wezlana® (ustekinumab) | Bristol-Myers Squibb’s Opdivo® (nivolumab) |
| Bayer’s Eylea® (aflibercept) | Merck’s Erbitux® (cetuximab) |
| AstraZeneca’s Enhertu® (trastuzumab deruxtecan) | AbbVie’s Humira® (adalimumab) |
| Celltrion’s Vegzelma® (bevacizumab) | |
| Celltrion’s Yuflyma® (adalimumab) | |
| AstraZeneca’s Saphnelo® (anifrolumab) | |
| Roche’s Tecentriq® (atezolizumab) | |
| UCB’s Bimzelx® (bimekizumab) |
In addition, a number of PBAC recommendations not accepted by applicants are set for review, including relating to AbbVie’s Skyrizi® (risankizumab), and Novartis’s Cosentyx® (secukinumab).